Background: The estimated worldwide annual incidence of MDR-TB is 480 000, representing 5% of TB incidence, but 20% of mortality. Multiple drugs have recently been developed or repurposed for the treatment of MDR-TB. Currently, treatment for MDR-TB costs thousands of dollars per course.
Introduction
TB is estimated to have caused 9 million new active infections and 1.5 million deaths worldwide in 2013. 1 An estimated 480 000 cases of TB annually are resistant to first-line drugs worldwide, resulting in so-called MDR-TB. 2 While global TB prevalence has remained relatively stable over the last two decades, detected cases of drug-resistant TB nearly tripled between 2009 and 2013. 1 MDR-TB represents 5% of global incidence, but nearly 20% of mortality. 1 9% of MDR-TB cases have further resistance (XDR-TB). 2 Furthermore, the proportion of cases that are drug resistant may be underestimated due to poor coverage of drug susceptibility testing. 3 Treatment success rates are 86% for drug-susceptible TB (DS-TB), 45% for MDR-TB and just 22% for XDR-TB. 1 The WHO categorizes TB medicines into Groups 1 (first-line), 2 (injectables), 3 (fluoroquinolones), 4 (bacteriostatics) and 5 (drugs for which limited evidence exists, including newer drugs). 2, 4 Group 5 includes several recently developed or repurposed treatments for drug-resistant TB: bedaquiline, delamanid, clofazimine and linezolid. Delamanid, approved in the EU, 2 and bedaquiline, approved in the EU and the USA, 5, 6 have been recently added to the WHO Model Essential Medicines List, along with linezolid. While many TB medicines have severe side effects, and require at least 20 months of treatment for MDR-TB and 24 months for XDR-TB, 2 several promising new 9 and 6 month combination regimens containing bedaquiline and/or pretomanid are currently under investigation for treating MDR-TB. Current trials investigating these regimens include STREAM, STAND, NC-005 and Nix-TB. [8] [9] [10] [11] The MDR-END trial will assess a longer regimen that includes delamanid. 12 Tuberculosis care regularly incurs high health expenditures in low-and middle-income countries, where 95% of notified TB cases are diagnosed. 1, 13 In 2013, more than 39 000 patients diagnosed with MDR-TB were on waiting lists for treatment. 1 Barriers to adequate treatment include low drug-susceptibility testing (DST) coverage, lack of access to laboratory-based diagnosis, lack of treatment monitoring, as well as high drug prices. 14, 15 For MDR-TB, where drugs alone cost thousands of dollars per patient, 14 sustainable price reductions could allow both scale-up of treatment and cost savings. The establishment of an effective generics market for novel MDR-TB regimens will require political prioritization, overcoming of patent barriers and adequate demand volume. Demand would in turn be driven by improved detection rates, increased evidence on optimal regimens and demand-side interventions such as pooled procurement by international funders and governments.
In HIV/AIDS, competitive generic production of antiretroviral medicines (ARVs) resulted in rapid price decreases, allowing treatment scale-up: 16 By mid-2014, 15 million people were receiving treatment. 17 More than 70% of ARVs used in low-and middleincome countries are manufactured by Indian generics companies. 18 In this analysis, we calculated estimated generic prices for new TB medicines, assuming robust competitive generic production.
Methods
We calculated estimated generic prices by combining data on the costs of the active pharmaceutical ingredient (API) with other cost components of manufacturing, using algorithms outlined below. Data on API exported from India were extracted from an online database for 2015. 19 Estimated generic prices were calculated for rifampicin, isoniazid, pyrazinamide, ethambutol, amikacin, kanamycin, levofloxacin, capreomycin, prothionamide and cycloserine for the purpose of validating our costing algorithms. Per-kilogram pricing data for exported API and algorithms were used to estimate generic prices for moxifloxacin, linezolid and clofazimine. Where robust export data were not available (bedaquiline, delamanid, sutezolid, pretomanid), we calculated estimated prices based on the processes used for the synthesis of these compounds. All monetary values are expressed as US dollars ($).
Costing algorithms
Previous price-estimation studies have combined API price with dosage information, formulation and packaging costs to estimate the generic price of the finished product.
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We developed algorithms based on information provided confidentially by multiple large generics companies, and by testing by comparing algorithm-predicted prices for Group 1-4 drugs (for which robust generic competition already exists) with current prices available through the Global Drug Facility (GDF). 23 These algorithms are described below and are shown as a flow chart in Figure 1 , using the example of moxifloxacin. The 'highdemand' algorithm represents a scenario in which market dynamics are similar to those of existing Group 1-4 medicines, while the 'low-demand' algorithm represents the early stages of global use and/or a limited scope of indications.
India is a major producer of generic medicines, producing more than 70% of HIV treatments used in low-and middle-income countries, 17 and all suppliers in long-term supply agreements with the GDF are generic companies manufacturing in India. 24 For generic price calculations, we thus assumed manufacturing in India.
A generics manufacturer quoted a formulation and primary packaging cost of $0.008 per pill, assuming production in a facility approved for export to the European market, and a batch size of 500 000 packaged tablets. We included a conversion cost of $0.01 per pill in the high-demand algorithm and $0.04 in the low-demand algorithm. These assumed conversion costs are greater than, i.e. conservative in relation to, those set out in the Indian National Pharmaceutical Pricing Authority's 'Norms for Conversion Cost (CC), Packing Charges (PC) and Process Loss (PL)'. 25 Excipient contents were gathered from information published by the originator companies (Table S1 , available as Supplementary data at JAC Online), and per-kilogram excipients costs were extracted from export data. Addition of excipient costs assumed that the total weight of excipients in a pill is 4 times that of the API, and that the whole excipient weight is made up of the most expensive excipient. A cost of $0.10 per month was included for packaging and package inserts in the high-demand algorithm, and $0.35 in the low-demand algorithm. Finally, a profit margin for manufacturers was added on top of all costs: 10% in the high-demand algorithm; 50% in the low-demand algorithm. These profit margins are in line with typical generic producer margins reported elsewhere. 26 For injectable drugs, the price per vial was extracted from export data (as API data were unavailable). To this, secondary packaging costs and profit margins were added as for the other groups.
Stringent Regulatory Authorities
The dominant mechanisms for API quality assurance are approval by a Stringent Regulatory Authority (SRA) or approval by the WHO's prequalification programme (PQP). Countries considered to have SRAs comprise EU member states, the USA, Japan, Canada, Switzerland, Australia, Norway and Iceland. 27 Meeting internationally variable regulatory requirements adds costs to API manufacture. For the antiretroviral market, export-import data would suggest that a 35%-50% incremental cost increase is common for SRAapproved APIs, which was confirmed in confidential discussion with large generics manufacturers. To recognize this variation in our generic price calculations, we used ranges of API prices to cover the higher API cost when produced at SRA standard, and the lower API cost for a 'non-SRA' standard.
Where sufficient export data were available, we derived the API price range by calculating a volume-weighted mean price for all exports to countries without SRAs ('non-SRA price'), and a volume-weighted mean price of exports to countries with SRAs ('SRA price'). For prothionamide, where data were available only for non-SRA exports, we multiplied the weighted mean 'non-SRA price' by 1.5 to derive a likely 'SRA price'.
For medicines where export data showed artificially large non-SRA to SRA price differences, presumed due to patent protection and other market barriers, we used a representative API price for the 'non-SRA price' based on substantial volumes sold at this price, and multiplied by 1.5 to derive an 'SRA price'. This was the case for moxifloxacin and linezolid, and graphs showing the wide distributions of prices for these APIs, and the representative prices chosen, are available as Figures S1 and S2.
For novel drugs where export data were not available, we estimated API costs based on the synthetic processes described in originator patents, assuming significant volume demand, process optimization work and price competition in the market.
Current prices
Current prices were gathered from the price catalogues of the GDF and Médecins Sans Frontières (MSF), national drug price databases and online Gotham et al.
price comparison websites (Table S2) . Exchange rates as of 16 June 2015 were used.
Total regimen costs
In calculations of total regimen costs for novel regimens currently under investigation, estimated generic prices were used for all Group 5 drugs and moxifloxacin, and current GDF prices were used for all other drugs.
Volume demand
Where Indian export data were available, we calculated the total volume exported in kilograms or number of vials, as applicable. For bedaquiline, delamanid, pretomanid and sutezolid, potential export volumes were Estimated generic prices of new TB drugs JAC calculated as the amount of API needed to produce sufficient treatments for 108 000 patients annually. This patient number derives from assuming treatment with the drug in question of 50% of those diagnosed with MDR-TB, unchanged epidemiology and a 60% improvement in MDR-TB detection rates among those diagnosed with TB (from the current 45% to 72%). 1 This assumed improvement in detection rates would be in line with the trend in detection rates over the period 2009-13. 1 
Results
Global overviews of lowest currently available prices are shown in Figure 2 . Current and calculated generic prices, patent expiry dates and export volumes are shown in Table 1 and Figure 3 . Current lowest and estimated generic prices of novel TB regimens are shown in Table 2 .
Group 1-4 drugs
Calculated generic price ranges for Group 1-4 drugs all overestimated or included current GDF prices, with the exception of moxifloxacin ( Figure 2 ).
Moxifloxacin
Export data showed a segmented market and rapid per-kilogram API price reductions over 2010-16 ( Figure S1 ). In this period, 27 tonnes of moxifloxacin API were exported in the price range $160-$200/kg (18% of total exported volume). We therefore estimated a non-SRA API price of $180, and an SRA price of $270/kg. This yielded an estimated generic price of $3.49-$7.91 per patient per month (Figure 1 ).
Bedaquiline
Based on current prices for raw materials and yields similar to those reported in the patent literature, it is clear that the advanced intermediates for making bedaquiline API are not expensive-they are rapidly synthesized in good yield from very inexpensive starting materials. However, the bond-making step that forms the chiral centre is difficult to execute in high yield, and the subsequent separation of enantiomers through classic resolution is reported to provide only modest yields of chirally pure API. We estimated the API price to be $1600-$2600/kg in the early years of production, depending on the overall recovery of chiral resolution, and assuming production in 100 kg batches (equivalent to about 5300 6 month treatments). Indian import data showed 181 kg of bedaquiline exported from Belgium to Bangalore in 2015, priced between $2288/kg and $3077/kg. On the basis of synthesis analysis and observed exports, we estimate bedaquiline API to cost $2300/kg for 'non-SRA' and $3450/kg for 'SRA' standards. Following the high-and low-demand algorithms, this yielded estimated generic prices for bedaquiline of $7.83-$17.22 per patient per month.
Delamanid and pretomanid
The route of synthesis for delamanid is short, consisting of three steps. Based on raw material costs and yields, the estimated API cost of production is between $230/kg and $350/kg. Additional costs of processing bring the API costs up to $320-$490/kg. Multiplying the upper bound by 1.5% gives an 'SRA price' estimate 
Linezolid and sutezolid
Export data showed a segmented market and rapid per-kilogram API price reductions over 2010-16 ( Figure S2 ). In 2010-16, 7.1 tonnes of exported linezolid API were priced in the range $130-$150/kg (16% of total exported volume). We thus estimate current linezolid prices to be $140/kg for non-SRA, and $210/kg for SRA API.
Based on the chemical similarity of sutezolid to linezolid, costs of synthesis are likely to be the same if sutezolid reaches similar volumes of production.
These API costs yielded estimated generic prices of $4.29-$9.25 per patient per month for linezolid or sutezolid.
Clofazimine
In 2015, 4.9 tonnes of exported clofazimine API were priced in the range $200-$230/kg (99.8% of all exports), with a volumeweighted mean price of $214/kg. 99.0% of exported clofazimine API was to Germany, likely due to a standing agreement. 14 We thus conclude that a price of $214/kg represents SRA-quality API, yielding an estimated generic price of $3.89-$10.72 per patient per month. Table S2 . For patent expiry, the year of the earliest basic (compound) patent expiry is shown. Numbers in square brackets are global demand estimates based on treatment of half of all of detected MDR-TB cases yearly (108 000 patients). Assumed treatment lengths: bedaquiline, delamanid, pretomanid, 6 months; sutezolid, linezolid, 20 months, based on WHO recommendations for treatment with linezolid. 2 All current available prices are those quoted in the GDF Product Catalogue except delamanid and bedaquiline (references in Table S2 ). Price for bedaquiline is mean per-month price over 6 months. For bedaquiline and delamanid, doses from WHO interim guidelines. 4, 6 Dose for sutezolid assumed equal to linezolid. a Doses/regimen design following WHO recommendations, assuming adult patient weighing 60 kg. As there were no API exports to SRA countries in 2015, we estimated the higher bound of the API price range for prothionamide by multiplying the price found for API exported to non-SRA countries by 1.5. c Bedaquiline 400 mg daily for 2 weeks, then 200 mg three times a week for 22 weeks. d Dosage assumed to be that used in most recent published clinical trial (NCT01498419). e NPP, no published prices.
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Discussion
Novel drugs for MDR-TB could be mass-produced at prices far below current levels. Bedaquiline could be produced for $8-$17/month (current lowest price $136/month), delamanid could be produced for $5-$16/month (current lowest price $283/month) and linezolid could be produced for $4-$9/month (current lowest price $193/month). While current lowest global prices for a full treatment course with MDR-TB combination regimens are in the range of $1800-$4600 for 'preferred' regimens not containing novel drugs, 14 novel regimens combined with competitive manufacture and widespread generic availability could allow around 5-10 times more MDR-TB cases to be treated within the current budgets. Table 1 . Price for bedaquiline is mean per-month price over 6 months. Price categories used for bedaquiline are as described by the originator; country membership of these categories is currently unknown.
14 Gotham et al.
The 9 month STREAM arm B regimen, a slight modification of the Bangladesh regimen that demonstrated a treatment success rate of 88%, 28 could be made available for less than $300 per treatment course-as much as 1 year of generic second-line HIV treatment. 29 In 2014, $173 million was spent on purchasing second-line drugs through the GDF, for 35 000 treatments, or enough to treat only 26% of estimated detected MDR-TB cases. 1, 30 At the highest estimated price for the STREAM B regimen, medicines to treat all 136 000 cases of MDR-TB detected annually would cost only $54 million. 1 The bedaquiline-containing STREAM arm C and D regimens could be produced for as little as $231 and $168 per patient per course, respectively (arm C, 80%-87% below current lowest prices; arm D, 80%-87% below current lowest prices). Pretomanid-based regimens could further reduce prices to $53-$276 per full treatment course. The MDR-END regimen, which includes delamanid and linezolid, could still cost less than $500 per patient despite its longer duration.
Our algorithms were validated as accurate and conservative when compared with current prices for Group 1-4 medicines, for which they either accurately predicted or overestimated current prices (Figure 2 ). An exception to this trend is moxifloxacin-this is unsurprising, as it is the only Group 1-4 drug included in this analysis that is currently patented in some markets.
While currently WHO guidelines recommend the use of newer medicines only if older drugs are likely to be ineffective, 2 affordable access may facilitate a change in the principles of regimen design. For example, Brigden et al. have proposed 'principles for designing 'Current lowest prices of pretomanid-containing regimens combine the highest calculated generic price estimate for pretomanid with known current lowest prices for other drugs. All current available prices are those quoted in the GDF Product Catalogue except delamanid and bedaquiline (references in Table S2 ). Doses/regimen design following recommendations in the Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis, assuming adult patient weighing 60 kg. 2 For bedaquiline and delamanid, doses from WHO interim guidelines. 4, 6 For sutezolid, dose assumed equal to linezolid. Regimen details from most recent published clinical trial protocols, trial registration numbers: STREAM NCT02409290, PaMZ NCT01498419, BPaZ NCT02193776 (loading dose schedule for DS-TB used), BPaL NCT02333799, MDR-END NCT02619994 (shortest total duration and lowest doses assumed). [8] [9] [10] [11] [12] Estimated generic prices of new TB drugs JAC future regimens', of which the first principle is that any new regimen 'should contain at least one new class of drug'. 3 These principles could be adopted more readily if price is removed as a barrier to access.
As of March 2015, fewer than 1000 patients had been treated with bedaquiline, though it has been available for more than 2 years. 31 In a new donation programme, the originator company (Janssen) has agreed to donate 30 000 treatment courses over 4 years, 32 but this amount is sufficient to treat fewer than 3.5% of MDR-TB cases detected over this period. 1 If demand for bedaquiline rises above this level, generic competition may provide a more effective mechanism for providing sustainable access.
Outside of the donation programme, Janssen uses a tiered pricing scheme for bedaquiline (Figure 3) . In upper-middle-income countries, which make up 26% of notified TB cases, estimated generic prices would represent a 97% price decrease from current levels. 1 In lower-middle-and low-income countries (69% of notified TB cases), the decrease would be 91%. 1 Access to delamanid, for which patents are held by the Japanese company Otsuka, has been even more limited. 15, 31, 33 It was recently announced that delamanid will be available to Global Fund-eligible countries for purchase via the GDF, priced at $1700 for the 6 month treatment course, 34 putting it above, for example, the average Indian annual income, and drawing criticism from MSF. 33, 35 Our estimated generic price would represent a 96% decrease.
The patent on pretomanid is owned by the TB Alliance-a partnership comprising public and private collaborators. Given this, we would not expect pretomanid to be priced with a large mark-up. Early engagement of multiple generic manufacturers will nevertheless be necessary to achieve affordable prices.
Linezolid, moxifloxacin and clofazimine, integral to novel regimens, can all be sustainably produced at significantly lower prices than are currently available through the GDF. Versions of clofazimine that are not SRA approved are already available in India at prices below our calculated potential prices.
India and China dominate the ARV market. 26 While our analysis assumed manufacture in India, we believe overall costs of production would not be significantly different if manufacture took place in China. India and China are similar across tax, labour and infrastructure costs, with India assessed as having lower operating costs in some market reports but not others. 36, 37 We are not aware of a data source for the price of exported Chinese API with which a comparative analysis could be undertaken. While API is generally cheaper when bought in China, compared with India, 26 this comparison is difficult to make in a 'like-for-like' manner. China has tended to have stricter patent protection, and therefore, historically, the entrance of Chinese producers into API markets is substantially delayed versus Indian suppliers. In addition, significantly more Indian companies than Chinese are GMP (Good Manufacturing Practice) certified for the production of ARVs; the WHO's PQP currently lists 161 products with manufacturing sites in India, compared with 3 in China. 37, 38 The Indian industry has tended to produce more complicated, more expensive APIs than China. Lastly, Indian manufacturers are also more experienced in manufacturing finished products, and in collaborating with large international agencies. 37, 39 Considering China's lower API costs but greater investments needed in quality approval, as well as the greater experience between international agencies and Indian producers, we believe that in the context of novel TB medicines, there is not likely to be a significant difference in costs of production. We expect that demand volume will play a larger role in determining the cost of APIs and finished pharmaceutical products (FPPs) for MDR-TB in the next few years than will any geographical differences between production sites.
Our analysis estimated the potential prices that could be achieved in the absence of barriers to competitive manufacture and pricing, such as intellectual property. Historically, overcoming these barriers has required significant political efforts. 40 Of these estimated generic prices, the highest level of uncertainty is associated with bedaquiline, due to the length of the synthetic process. Price reductions would rely on sufficient demand. It is likely that reaching sufficient volume demand to spur a competitive market will be more difficult in MDR-TB than in HIV/AIDS, due to the smaller number of people affected. However, in 2002, when the global number of people on HIV/ AIDS treatment was still below half a million, 18 prices had already dropped 98% since 2000, despite there being only two WHO-prequalified manufacturers, to prices that allowed significant scale-up of global treatment. 16 In this period, the number of patients receiving antiretroviral treatment was similar to the number of patients that currently need MDR-TB treatment, per year (between 100 000 and 200 000). 18 Sufficient demand will require rapid adoption of new regimens, and improved diagnosis to identify eligible cases. If current trials find toxicity levels that are unacceptable for large-scale programmes, this will limit demand and thus slow price reductions. Funds saved through price reductions can be invested in diagnostics, case detection and improved surveillance-measures that will in turn contribute to maintaining robust demand for newer medicines.
Lastly, a fragmented market of many simultaneous treatment options may keep prices high. Such market fragmentation has indeed been a historic hallmark of global MDR-TB treatment. Treatment standardization could counteract this by allowing larger orders for a restricted range of novel medicines, thus encouraging price decreases.
Numerous actors bear responsibility for enabling robust, competitive generic manufacture of newer MDR-TB medicines. Commitment to scale-up MDR-TB treatment programmes by governments of high-burden countries and international funders, including improvement of DST coverage, and the endorsement of a single novel MDR-TB regimen by the WHO, would contribute to securing adequate demand volume for newer drugs. Much-needed clinical trials are taking place, but are run by non-profit initiatives such as the TB Alliance; continued work will depend on continued philanthropic or international aid funding. Licensing by the originator to the Medicines Patent Pool would likely be the quickest mechanism by which to remove patent barriers to competitive generic production of novel MDR-TB drugs. The Pool has recently announced an intention to expand its mandate to include newer TB medicines. 41 If this is not possible, compulsory licensing could provide an alternative route to enabling generic production.
Conclusions
Generic production could make it possible to supply treatments for all cases of MDR-TB with newer medicines and regimens with expenditure equivalent to, or less than, that currently spent on treating a small proportion of cases with second-line medicines.
When the benefits of new regimens are confirmed, delaying access to, and expansion of, treatment will lead to the loss of lives and forgone savings. Ensuring prompt generic competition can allow greatly improved cost efficiency and access to treatment.
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